Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
AMP-007 is a Phase 1/2 study for the treatment of advanced, previously treated multiple
myeloma. The first phase of the study is designed to determine a safe dose of imexon that can
be given to patients with advanced, previously-treated multiple myeloma. The Phase 2 part of
the study is designed to provide additional safety data and to gain an understanding of
whether imexon can improve the outcome for patients with multiple myeloma